Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
Abstract The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize respons...
| Auteurs principaux: | , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
BMC
2021-08-01
|
| Collection: | Breast Cancer Research |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s13058-021-01459-y |